Last reviewed · How we verify
Xarelto
At a glance
| Generic name | Xarelto |
|---|---|
| Also known as | Rivaroxaban |
| Sponsor | University Hospital, Montpellier |
| Target | Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Deep venous thrombosis
- Nonvalvular atrial fibrillation
- Peripheral arterial disease
- Prevention of atherothrombotic events after an acute coronary syndrome
- Prevention of atherothrombotic events at high risk of ischaemic events
- Prevention of atherothrombotic events in symptomatic peripheral artery disease
- Prevention of deep vein thrombosis
- Prevention of pulmonary embolism
- Prevention of stroke caused by a clot in a blood vessel in the brain
- Prevention of systemic embolism caused by a clot in a blood vessel
- Prevention of venous thromboembolism from re-occuring
- Prevention of venous thromboembolism in undergoing surgery
- Pulmonary embolism
- Stroke prevention
- Venous thromboembolic disease
Common side effects
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xarelto CI brief — competitive landscape report
- Xarelto updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI